An exploratory study on optimizing the administration time of furquintinib combined with camrelizumab in the third-line treatment of MSS late colorectal cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: Test group:Camrelizumab + Fruquintinib Primary outcome(s): progression-free survival Study Design: Single arm
创建时间：
2021-07-15
